<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02024009</url>
  </required_header>
  <id_info>
    <org_study_id>OCTO_063</org_study_id>
    <nct_id>NCT02024009</nct_id>
  </id_info>
  <brief_title>Systemic Therapy and Chemoradiation in Advanced Localised Pancreatic Cancer - 2</brief_title>
  <acronym>SCALOP-2</acronym>
  <official_title>A Multi-centre Randomised Study of Induction Chemotherapy Followed by Capecitabine (+/-Nelfinavir) With High or Standard Dose Radiotherapy for Locally Advanced Non-metastatic Pancreatic Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Oxford</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Celgene</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Cancer Research UK</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Oxford</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the role of increasing radiotherapy dose and addition of nelfinavir
      to chemoradiotherapy (CRT) in patients with inoperable pancreatic cancer that has not spread
      beyond the pancreas.

      Currently in the United Kingdom (UK), either chemotherapy alone or chemotherapy followed by
      CRT can be used in the management of inoperable pancreatic cancer that has not spread. CRT
      consists of 25-30 radiotherapy treatments in combination with chemotherapy. Although this
      treatment is effective in controlling local symptoms and slowing down the pace of cancer, in
      most cases it is unable to shrink it enough to make it operable. Some of the reasons for this
      could be the lack of oxygen and lack of blood flow within the tumour making it resistant to
      the effects of CRT. This study will investigate whether increasing the dose of radiotherapy,
      or increasing the oxygen and blood supply to the tumour by giving nelfinavir, or a
      combination of both, can improve outcomes. We also want to know what the additional
      toxicities from such intensive approaches are.

      All participants will initially receive 12 weeks of chemotherapy, and those with stable or
      responding disease will receive further study treatment. The treatment allocation to 1 of the
      5 options outlined below will be done at random by computer and neither the doctor nor the
      patient can choose the treatment option. The process of randomisation ensures that all
      treatment arms are equally balanced in terms of patient and tumour characteristics, and to
      reduce the possibility of bias.

      The study will consist of 2 stages. In the 1st stage we aim to find the right dose of
      nelfinavir to combine with CRT, and this will require around 27 participants of whom up to 18
      will receive nelfinavir together with CRT. In the 2nd stage, we want to find out the benefits
      of this approach over and above standard treatments and therefore we will recruit the order
      of 262 participants and allocate 170 to 1 of the 5 following treatment arms:

      Arm A: Nelfinavir together with CRT Arm B: CRT (without nelfinavir) Arm C: Nelfinavir
      together with CRT (but using a higher than conventional dose of radiotherapy) Arm D: CRT
      without nelfinavir (but using a higher than conventional dose of radiotherapy) Arm E:
      Chemotherapy alone (without radiotherapy) Participants who are ineligible or refuse
      randomisation will be treated as per local standard but will remain in the study for follow
      up at 26, 39 and 52 weeks. Their data will contribute to an Overall Survival (OS) analysis.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2016</start_date>
  <completion_date type="Anticipated">August 2020</completion_date>
  <primary_completion_date type="Anticipated">August 2020</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Toxicity</measure>
    <time_frame>12 months</time_frame>
    <description>Common Toxicity Criteria for Adverse Effects (CTCAE) v 4.02</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>12 months</time_frame>
    <description>European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaires (QLQ) - C30 and PAN26 for pancreatic cancer.</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">289</enrollment>
  <condition>Pancreatic Neoplasms (Locally Advanced Non-metastatic)</condition>
  <arm_group>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>12 weeks (3 cycles) of induction Gemcitabine and Nab-paclitaxel (GEMABX) chemotherapy then 1 cycle of GEMABX* whilst radiotherapy (RT) planned then capecitabine (830mg/m2 oral bd) + Nelfinavir** + 50.4 Grays (Gy) in 28#
*1 cycle GEMABX = 28 day cycle of intravenous Abraxane 125mg/m2 followed by gemcitabine 1000mg/m2 on day 1, 8 and 15.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>12 weeks (3 cycles) of induction GEMABX chemotherapy then 1 cycle of GEMABX* whilst RT planned then capecitabine (830mg/m2 oral bd) + 50.4Gy in 28#
*1 cycle GEMABX = 28 day cycle of intravenous Abraxane 125mg/m2 followed by gemcitabine 1000mg/m2 on day 1, 8 and 15.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>12 weeks (3 cycles) of induction GEMABX chemotherapy then
1 cycle of GEMABX* whilst RT planned then capecitabine (830mg/m2 oral bd) + Nelfinavir** + 60Gy in 30#
*1 cycle GEMABX = 28 day cycle of intravenous Abraxane 125mg/m2 followed by gemcitabine 1000mg/m2 on day 1, 8 and 15</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>12 weeks (3 cycles) of induction GEMABX chemotherapy then
1 cycle of GEMABX* whilst RT planned then capecitabine (830mg/m2 oral bd) + 60Gy in 30#
*1 cycle GEMABX = 28 day cycle of intravenous Abraxane 125mg/m2 followed by gemcitabine 1000mg/m2 on day 1, 8 and 15.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm E</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>6 cycles of GEMABX*
*1 cycle GEMABX = 28 day cycle of intravenous Abraxane 125mg/m2 followed by gemcitabine 1000mg/m2 on day 1, 8 and 15.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>nab-paclitaxel</intervention_name>
    <description>Abraxane is a proprietary solvent-free, protein-stabilized formulation of paclitaxel comprised of paclitaxel and human albumin in a noncrystalline amorphous state</description>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_label>Arm B</arm_group_label>
    <arm_group_label>Arm C</arm_group_label>
    <arm_group_label>Arm D</arm_group_label>
    <arm_group_label>Arm E</arm_group_label>
    <other_name>Abraxane</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>60Gy in 30#</intervention_name>
    <arm_group_label>Arm C</arm_group_label>
    <arm_group_label>Arm D</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>50.4Gy in 28#</intervention_name>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_label>Arm B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nelfinavir</intervention_name>
    <description>VIRACEPTÂ® (nelfinavir mesylate) is an inhibitor of the human immunodeficiency virus (HIV) protease.</description>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_label>Arm C</arm_group_label>
    <other_name>Viracept</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Capecitabine</intervention_name>
    <description>Given in combination with gemcitabine, known as GemCap.</description>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_label>Arm B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine</intervention_name>
    <description>Gemcitabine is indicated for treatment of patients with locally advanced or metastatic adenocarcinoma of the pancreas. It is administered as an infusion</description>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_label>Arm B</arm_group_label>
    <arm_group_label>Arm C</arm_group_label>
    <arm_group_label>Arm D</arm_group_label>
    <arm_group_label>Arm E</arm_group_label>
    <other_name>GEMZAR</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          1. 1. Aged 18 years or over

          2. Histologically or cytologically proven carcinoma of the pancreas

          3. Locally advanced, non-metastatic inoperable disease as per NCCN criteria (APPENDIX 2).
             The following types of interventions are allowed:

               1. Palliative bypass procedure

               2. Common bile duct stenting

          4. Primary pancreatic lesion 6 cm or less in diameter (taken from scan results)

          5. WHO PS 0-1 (APPENDIX 1)

          6. Adequate haematological function: neutrophils â¥1.5 x 109/L, platelets â¥100 x 109/L and
             haemoglobin â¥100g/L

          7. Adequate liver function tests:

               1. Serum bilirubin â¤1.5 x ULN. In participants who have had a recent biliary drain
                  and whose bilirubin is improving, a value of â¤3 x ULN is acceptable, however
                  treatment should not start unless Bilirubin is â¤1.5 x ULN.

               2. AST and/or ALT â¤ 3 x ULN.

          8. Adequate renal function (GFR â¥ 50ml/min (Cockcroft &amp; Gault - APPENDIX 3))

          9. Written informed consent obtained

         10. Women of child-bearing potential must have negative serum or urine pregnancy test
             within 14 days prior to registration, must agree to use a highly effective
             contraception method during GEMABX treatment and for 30 days after last administration
             of GEMABX and to use an acceptable contraception method during chemoradiotherapy and
             for 6 months after completion of all treatment.

         11. Male patients must be surgically sterile or must agree to use a condom during GEMABX
             treatment and for 90 days after last administration of GEMABX, and to use a condom
             during chemoradiotherapy and for three months after completion of chemoradiotherapy.

        Exclusion criteria:

          1. Primary resectable cancer of the pancreas.

          2. Distant metastases

          3. Pregnant or breast-feeding patients.

          4. Any evidence of severe uncontrolled systemic diseases including uncontrolled coronary
             artery disease, myocardial infarction or stroke within the last 6 months, any major
             systemic or psychiatric co-morbidities or any other considerations that the PI judges
             might impact on patient safety or protocol compliance and achievement of the study
             aims.

          5. Previous malignancies in the preceding 3 years except for:

               1. In situ cancer of the uterine cervix

               2. Adequately treated basal cell skin carcinoma

               3. Adequately treated early stage non-pancreatic malignancy in complete remission
                  for at least 3 years

          6. Renal abnormalities including adult polycystic kidney disease or hydronephrosis or
             ipsilateral single kidney (i.e. functioning right kidney for head tumours; left kidney
             for tail tumours) that may preclude upper abdominal radiotherapy without damaging
             functional kidneys.

          7. Previous RT to upper abdomen

          8. Recurrent cancer following definitive pancreatic surgery

          9. Lymphoma or neuroendocrine tumours of the pancreas

         10. Known haemophilia A and B, chronic hepatitis type B or C.

         11. Other experimental treatment 6 weeks or less prior to registration into this study
             (including chemotheraÂ¬py and immunotherapy).

         12. Known hypersensitivity to any of the IMPs or any of their excipients.

         13. Known dihydropyrimidine dehydrogenase (DPD) deficiency

         14. Known galactose intolerance, Lapp-lactose deficiency or glucose-galactose
             malabsorption

         15. History of severe unexpected reaction to fluoropyrimidine therapies

         16. If the following concomitant medications cannot be discontinued temporarily during the
             CRT phase then the patients cannot enter the trial:

               1. Sorivudine and analogues e.g. brivudine

               2. Methotrexate.

               3. Allopurinol and dipyridamole

         17. Known HIV positive disease (but routine screening for HIV is not required)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Somnath Mukherjee, MD, FRCP, FRCR</last_name>
    <role>Principal Investigator</role>
    <affiliation>somnath.mukherjee@oncology.ox.ac.uk</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Claire Hamill, MSc</last_name>
    <phone>01865 617078</phone>
    <email>octo-scalop-2@oncology.ox.ac.uk</email>
  </overall_contact>
  <location>
    <facility>
      <name>Oxford University Hospitals, Churchill Cancer Centre</name>
      <address>
        <city>Headington</city>
        <state>Oxfordshire</state>
        <zip>OX3 7LE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Dr Somnath Mukherjee</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Bristol Haematoloy and Oncology Centre</name>
      <address>
        <city>Bristol</city>
        <zip>BS2 8ED</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Dr Stephen Falk</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Addenbrookes Hospital</name>
      <address>
        <city>Cambridge</city>
        <zip>CB2 0QQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Dr Thankamma Ajithkumar</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Velindre Cancer Centre</name>
      <address>
        <city>Cardiff</city>
        <zip>CF14 2TL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Dr Seema Arif, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Castle Hill Hospital</name>
      <address>
        <city>Cottingham</city>
        <zip>HU16 5JQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Dr Rajarshi Roy</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital</name>
      <address>
        <city>Coventry</city>
        <zip>CV2 2DX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Dr Martin Scott-Brown</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Surrey County Hospital</name>
      <address>
        <city>Guildford</city>
        <zip>GU2 7XX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Dr Sebastian Cummins</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St James' Hospital</name>
      <address>
        <city>Leeds</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Dr Ganesh Radhakrishna</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University College London Hospital</name>
      <address>
        <city>London</city>
        <zip>NW1 2BU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Dr John Bridgewater</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Free Hospital</name>
      <address>
        <city>London</city>
        <zip>NW3 2PF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Dr Roopinder Gillmore</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hammersmith Hospital</name>
      <address>
        <city>London</city>
        <zip>W12 0HS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Dr Harpreet Wasan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 23, 2013</study_first_submitted>
  <study_first_submitted_qc>December 30, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 31, 2013</study_first_posted>
  <last_update_submitted>July 4, 2017</last_update_submitted>
  <last_update_submitted_qc>July 4, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>chemoradiotherapy</keyword>
  <keyword>nelfinavir</keyword>
  <keyword>abraxane</keyword>
  <keyword>gemcitabine</keyword>
  <keyword>radiotherapy</keyword>
  <keyword>capecitabine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Nelfinavir</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

